|
|
|
|
Vol. 303, Issue 2, 557-562, November 2002
Laboratory of Molecular Neuropharmacology, Memorial Sloan-Kettering
Cancer Center and the Program in Neuroscience, the Weill Graduate
School of Medical Sciences of Cornell University, New York, New York
(E.A.B., G.W.P.), and Department of Pharmacology, Temple University
Medical School, Philadelphia, Pennsylvania (R.J.T.)
Pharmacological differences among µ opioid drugs have been observed
in in vitro and in vivo preclinical models, as well as clinically,
implying that all µ opioids may not be working through the same
mechanism of action. Here we demonstrate analgesic synergy between
L-methadone and several µ opioid ligands. Of the
compounds examined, L-methadone selectively synergizes with
morphine, morphine-6
-glucuronide, codeine, and the active metabolite
of heroin, 6-acetylmorphine. Morphine synergizes only with
L-methadone. In analgesic assays, D-methadone
was inactive alone and did not enhance morphine analgesia when the two
were given together, confirming that L-methadone was not
acting through N-methyl-D-aspartate
mechanisms. Both L-methadone and morphine displayed only
additive effects when paired with oxymorphone, oxycodone, fentanyl,
alfentanyl, or meperidine. Although it displays synergy in analgesic
assays, the L-methadone/morphine combination does not
exhibit synergy in the gastrointestinal transit assay. This analgesic
synergy of L-methadone with selective µ opioid drugs and
the differences in opioid-mediated actions suggest that these drugs may
be acting via different mechanisms. These findings provide further
evidence for the complexity of the pharmacology of µ opioids.
This article has been cited by other articles:
![]() |
Y.-X. Pan, J. Xu, M. Xu, G. C. Rossi, J. E. Matulonis, and G. W. Pasternak Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions PNAS, March 24, 2009; 106(12): 4917 - 4922. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Tallarida An Overview of Drug Combination Analysis with Isobolograms J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 1 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Lemberg, V. K. Kontinen, K. Viljakka, I. Kylanlahti, J. Yli-Kauhaluoma, and E. Kalso Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat. Anesth. Analg., June 1, 2006; 102(6): 1768 - 1774. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Marcou, S. Marque, J.-X. Mazoit, and D. Benhamou The Median Effective Dose of Tramadol and Morphine for Postoperative Patients: A Study of Interactions Anesth. Analg., February 1, 2005; 100(2): 469 - 474. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Grabovsky and R. J. Tallarida Isobolographic Analysis for Combinations of a Full and Partial Agonist: Curved Isoboles J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 981 - 986. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Tallarida, A. Cowan, and R. B. Raffa Antinociceptive Synergy, Additivity, and Subadditivity with Combinations of Oral Glucosamine Plus Nonopioid Analgesics in Mice J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 699 - 704. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. A. Kolesnikov, M. Cristea, and G. W. Pasternak Analgesic Synergy Between Topical Morphine and Butamben in Mice Anesth. Analg., October 1, 2003; 97(4): 1103 - 1107. [Abstract] [Full Text] [PDF] |
||||